Antibody Drug Conjugates (ADCs)

Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley.

The British-Swedish drugmaker has announced plans to build a US$1.5 billion facility in Singapore for the manufacturing of antibody–drug conjugates (ADCs) to complement their existing cancer drug portfolio. 

AbbVie and Genmab recently received approval from the US FDA for their joint venture, the blood cancer therapy epcoritamab, sold under the brand name EPKINLY. 

Roche launches into a new agreement with Zion Pharma, a leading Chinese pharmaceutical company, to help develop and commercialise their flagship small molecule tyrosine kinase inhibitor, ZN-A-1041. 

Pfizer makes a bold move in the acquisition of innovative cancer therapy biotechnology company Seagen, the move means the doubling of their pipeline of early-stage therapeutics and gaining four leading ADC therapies. 

The latest results from a Phase II clinial trial into Enhertu shows consistently promising results, with a durable response in patients with various HER2-expressing tumours. 

Trodelvy, an antibody–drug conjugate with indications against certain types of cancer, has been approved by the US FDA for a third indication against pre-treated HR+/HER2- metastatic breast cancer.

A carefully curated list of the most notable drug approvals of the past year, covering neurology, oncology, and COVID-19, as well as a look at the most promising drugs up for review in 2023. 

Merck tests new formulation of effective immunotherapy Keytruda to gain approval in time to extend the patent on the drug before it runs out in 2028. 

A monoclonal antibody drug, named lecanemab, has been tested in a Phase III clinical trial in nearly 1800 participants, with promising results in reducing the effects of Alzheimer's disease on the brain. 

GSK has released a statement on the failure of Blenrep in achieving the main goals of a late-stage study for the blood cancer therapeutic, raising concerns of regulatory approval being rescinded.

Merck opens their latest commercial manufacturing facility in Martillac, France, boasting rapid development and commercialisation of drug products with streamlined processes and state-of-the-art technology.